Margret Rave-Fränk1, Narges Tehrany1, Julia Kitz2, Martin Leu1, Hanne Elisabeth Weber1, Peter Burfeind3, Henning Schliephake4, Martin Canis5, Tim Beissbarth6, Holger Michael Reichardt7, Hendrik Andreas Wolff8. 1. Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. 2. Department of Pathology, University Medical Center Göttingen, 37099, Göttingen, Germany. 3. Department of Human Genetics, University Medical Center Göttingen, 37099, Göttingen, Germany. 4. Department of Oral and Maxillofacial Surgery, University Medical Center Göttingen, 37099, Göttingen, Germany. 5. Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Göttingen, 37099, Göttingen, Germany. 6. Institute of Medical Statistics, University Medical Center Göttingen, 37099, Göttingen, Germany. 7. Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, 37099, Göttingen, Germany. 8. Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. hendrik.wolff@med.uni-goettingen.de.
Abstract
OBJECTIVE: The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy. METHODS: Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16(INK4A) status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression. RESULTS: CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16(INK4A) positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034). CONCLUSION: A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.
OBJECTIVE: The chemokine CXCL12 and its receptor CXCR4 can affect tumor growth, recurrence, and metastasis. We tested the hypothesis that the CXCL12 and CXCR4 expression influences the prognosis of patients with inoperable head and neck cancer treated with definite radiotherapy or chemoradiotherapy. METHODS:Formalin-fixed paraffin-embedded pretreatment tumor tissue from 233 patients with known HPV/p16(INK4A) status was analyzed. CXCL12 and CXCR4 expressions were correlated with pretreatment parameters and survival data by univariate and multivariate Cox regression. RESULTS:CXCL12 was expressed in 43.3 % and CXCR4 in 66.1 % of the samples and both were correlated with HPV/p16(INK4A) positivity. A high CXCL12 expression was associated with increased overall survival (p = 0.036), while a high CXCR4 expression was associated with decreased metastasis-free survival (p = 0.034). CONCLUSION: A high CXCR4 expression could be regarded as a negative prognostic factor in head and neck cancer because it may foster metastatic spread. This may recommend CXCR4 as therapeutic target for combating head and neck cancer metastasis.
Entities:
Keywords:
Chemokines; Head and neck cancer; Prognosis; Radio(chemo)therapy; Squamous cell cancer
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: Robert P Takes; Alessandra Rinaldo; Carl E Silver; Missak Haigentz; Julia A Woolgar; Asterios Triantafyllou; Vanni Mondin; Daniela Paccagnella; Remco de Bree; Ashok R Shaha; Dana M Hartl; Alfio Ferlito Journal: Oral Oncol Date: 2012-04-18 Impact factor: 5.337
Authors: Hendrik A Wolff; Benjamin Daldrup; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M W Roedel; Hans Christiansen Journal: Radiology Date: 2011-03 Impact factor: 11.105
Authors: David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy Journal: Blood Date: 2014-02-12 Impact factor: 22.113
Authors: Catherine M Barnett; Ryan S Sommerville; Charles Lin; Gishan Ratnayake; Brett Hughes; Touraj Taheri Journal: J Neurol Surg B Skull Base Date: 2018-06-14
Authors: S Nagl; M Haas; G Lahmer; M Büttner-Herold; G G Grabenbauer; R Fietkau; L V Distel Journal: Oncoimmunology Date: 2016-01-13 Impact factor: 8.110
Authors: Harsh Samarendra; Keaton Jones; Tatjana Petrinic; Michael A Silva; Srikanth Reddy; Zahir Soonawalla; Alex Gordon-Weeks Journal: Br J Cancer Date: 2017-05-23 Impact factor: 7.640
Authors: Kun Li; Chengcheng Zhang; Lei Chen; Pingping Wang; Yang Fang; Junwei Zhu; Shuo Chen; Juan Du; Bing Shen; Kaile Wu; Yehai Liu Journal: PeerJ Date: 2019-06-11 Impact factor: 2.984